drugset

drugset / Trial / NCT07643870

Human ADME Study of [14C]-AZD1390

NCT07643870 ↗

Phase 1 Not yet recruiting 8 enrolled AstraZeneca

NaSingle-groupOpen-labelTreatment

Summary

This is a Phase I, multicentre, single-dose, open-label study to assess the absorption, distribution, metabolism, and excretion of \[14C\]-AZD1390.

Timeline

Start: 2026-06-30
Primary completion: 2028-04-12
Completion: 2028-04-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AZD1390	Small molecule	—	Oral

Indications